Biotechs Bounce Off Bottom On Novartis Deal But Fade Later In The Day

Normally this kind of M&A news would be an opportunity to load up on biotechs but technicals are still weak and crosscurrents from economic and macro news create a risk-off sentiment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.